How can vomiting or diarrhoea on GLP-1 therapy lead to kidney problems?

Severe or persistent vomiting or diarrhoea can cause fluid loss and dehydration, which reduces blood flow to the kidneys and can precipitate acute kidney injury. Acute kidney injury events have been reported in association with severe GI events on incretin therapy, particularly during dose escalation.

Who is at higher risk of dehydration-related kidney injury?

Those with pre-existing chronic kidney disease, and people taking diuretics or RAAS-acting medicines (such as ACE inhibitors or ARBs), carry greater risk if severe GI events occur. Dose escalation phases are also associated with higher risk than stable maintenance dosing.

Does the FLOW trial tell us GLP-1 medicines harm the kidneys?

The FLOW trial specifically examined semaglutide in people with type 2 diabetes and chronic kidney disease and addresses kidney outcomes in that population — it was not designed to isolate the dehydration/AKI pathway discussed here. Most other pivotal trials exclude advanced CKD populations, which limits what trial data alone can tell us about renal risk in higher-risk groups more broadly.

What symptoms of dehydration should prompt urgent review?

Persistent vomiting or diarrhoea combined with reduced urine output, dizziness or marked thirst warrants urgent qualified clinical assessment rather than self-management. This is particularly important for anyone with known chronic kidney disease or taking diuretic or RAAS-acting medicines.

Dehydration and renal risk

Severe vomiting or diarrhoea on incretin therapy can precipitate dehydration, which may worsen renal function — particularly in those with pre-existing chronic kidney disease, on diuretics, or on RAAS-acting medicines.

What is known

Acute kidney injury events have been reported in association with severe GI events on therapy.
Dose escalation and high-baseline-CKD populations carry greater risk.

What remains uncertain

Optimal monitoring frequency during titration in higher-risk populations.

Trial limitations

Trial populations often exclude advanced CKD; FLOW addresses T2D + CKD specifically.

FAQs

How can vomiting or diarrhoea on GLP-1 therapy lead to kidney problems?: Severe or persistent vomiting or diarrhoea can cause fluid loss and dehydration, which reduces blood flow to the kidneys and can precipitate acute kidney injury. Acute kidney injury events have been reported in association with severe GI events on incretin therapy, particularly during dose escalation.
Who is at higher risk of dehydration-related kidney injury?: Those with pre-existing chronic kidney disease, and people taking diuretics or RAAS-acting medicines (such as ACE inhibitors or ARBs), carry greater risk if severe GI events occur. Dose escalation phases are also associated with higher risk than stable maintenance dosing.
Does the FLOW trial tell us GLP-1 medicines harm the kidneys?: The FLOW trial specifically examined semaglutide in people with type 2 diabetes and chronic kidney disease and addresses kidney outcomes in that population — it was not designed to isolate the dehydration/AKI pathway discussed here. Most other pivotal trials exclude advanced CKD populations, which limits what trial data alone can tell us about renal risk in higher-risk groups more broadly.
What symptoms of dehydration should prompt urgent review?: Persistent vomiting or diarrhoea combined with reduced urine output, dizziness or marked thirst warrants urgent qualified clinical assessment rather than self-management. This is particularly important for anyone with known chronic kidney disease or taking diuretic or RAAS-acting medicines.